chrisvoncsefalvay/vaers-outcomes huggingface dataset:
The pt experienced flu-like symptoms with 1st vaccine. After 2nd vaccine the pt experienced memory loss, shortness of breath, headaches, mood swings, confusion, fatigue, dizziness, joint pain, which is ongoing. The pt was treated again with antibiotics (long term). He continues to have problems and is still on antibiotics at this time. The follow up received on 3/7/02 states, "flu like symptosm dr gave 2nd inject. didn't think it was a reaction. My husband now has neurological problems from vaccine. My husbnad was diagnosed with Lyme disease in June of 1999. He had a very bad rash that wrapped around his chest. Engulfing his heart. He also had flu like symptoms. His regular doctor went over the dematologists suggestion of spinal tap and IV antibiotics, and pt received 3 weeks of antibiotics which only helped somewhat. In the fall it was suggested he get the lymerix vaccine against my better judgement, since I only work with animals. We would nevere give a vaccine to a pet with Lyme disease. So agian my husband listened t o his doctor and got the vaccine 3/3/00. By the 10th he was complaining about flu like symptosm again... his doctor brushed it off and gave the second dose of lymerix 4 weeks later. My husband has been struggling with neurological problems ever since. At that point I pushed for the IV antibiotic treatment which helped a bit but by April of 2001 the memory, concentration, achy joints, just feeling sick reoccurred. We are now seeing a doctor out of state since no one seems to know how to treat him up here. I am very upset this vaccine was ever put on the market and I think the ones responsible should pay. We did refuse the booster vaccine in March 2001."
Cough; Sore throat; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Cough) and OROPHARYNGEAL PAIN (Sore throat) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced COUGH (Cough) and OROPHARYNGEAL PAIN (Sore throat). At the time of the report, COUGH (Cough) and OROPHARYNGEAL PAIN (Sore throat) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment information was provided.   Reporter did not allow further contact
Chills and fever started  12 hours after 2nd dose. Significant Full body aches, fever, headache, fatigue increased significantly. this lasted until 36 hours after the dose. Headache continued and lasted for 2 weeks after the 2nd dose
COVID-19 treatment; COVID-19 treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 61-year-old female patient (not pregnant) received bnt162b2, bnt162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 22Sep2022 as dose 5 (booster), single (Lot number: Gh9703) at the age of 60 years for covid-19 immunisation; bnt162b2 (BNT162B2), on 15Apr2022 as dose 4 (booster), single (Lot number: Fm9992) for covid-19 immunisation; covid-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Allergy: latex" (unspecified if ongoing). Concomitant medication(s) included: VITAMIN D NOS; VAGIFEM. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19 treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Patient received other vaccine and medication in 2 weeks. Paxlovid was given as treatment for COVID-19 from 07Sep2023 to 12 Sep2023
Injection given around 9 AM; chills around 6 PM; awoke at 1130 PM with fever 101.8, skin hot to touch; runny nose; headache over eyes; a little dizzy; some facial swelling.
Swollen arm at inject site. Achy muscles. 6 to 8 cm across.
Started having numbness in foot, progressing to leg 2 mos after Anthrax shot, which went up to arm. Also, complains of fatigue.
low grade fever; This is a spontaneous report from a Pfizer-sponsored program via a contactable nurse (patient wife). A male patient (husband) of an unspecified age received the second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number not reported), via an unspecified route of administration on an unspecified date at single dose for covid-19 immunization. The patient medical history and concomitant medications were not reported. The patient received his first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) on an unspecified date for covid-19 immunization. It was reported that her husband had a low grade fever after 24 hours of receiving his second dose covid vaccine. The outcome of the event was unknown.  Information on the batch/lot number has been requested.
12/21/2021 Covid symptoms started. I was perfectly fine in the morning and felt good, but after lunch I sat down and felt a little tired and just not right as the afternoon went on. I had a sore throat and start of a cough that evening and I was supposed to work that evening but they told me to stay home. I also had congestion and the cough and my throat wasn't sore after the first day but I had the cough for a couple of days after but I'm not sure how many days, but I walked around with a water bottle and took Mucinex. Friday I was starting to feel better but I had no energy and I just lived off the couch for the next few days. Today I started with a runny nose. I had done a pcr test at home which was positive and my daughter had gotten me a pulse ox that would get down to 93 but it was mostly at 95.
This spontaneous report was received from a physician regarding a 2 year old female patient. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 19-JUL-2017 the patient was vaccinated with VAQTA 25/0.5, lot # M036459 with expiration date 18-JAN-2018 (dose was not reported), intramuscularly for routine vaccine. On 31-JUL-2017, the patient experienced itchy rash like hives all over her body (rash generalized) and itchy eyes (eye pruritus). The patient received unspecified medication as a treatment for the events. The outcome of rash generalised and eye pruritus was unknown. Causality assessment was not provided by the reporter. Additional information has been requested.
2ml of normal saline was used to dilute vaccine instead of the recommended 1.8ml of normal saline.
The patient lives in a group home.  He has a history of seizures with occasional breakthrough.  On 1/24/22 at ~4 am he had a cluster of seizures and a fever of 102.0F.  The staff called 911 and he was taken to the Hospital and admitted for observation.  All the details of the hospitalization and treatment are not known now.  His group home staff person who was at the hospital with him reported that he was back to his baseline after 1 day.  He remained in the hospital for video EEG monitoring.  The studies will be reviewed by neurology to determine if medication changes are needed.  His discharge is planned for tomorrow (1/28/2021).
This spontaneous report as received from a currently 77 years old female consumer reporting on herself without drug reactions or allergies. The patient's medical history included shingles for the first time in approximately 1999 (reported as 15 years ago) and has many outbreaks since then. About 1-2 years ago, the patient was vaccinated with ZOSTAVAX (dose, route, strength, lot number and expiration date were not reported). Secondary therapies were not reported. Concomitant therapies included ZOCOR and pantoprazole. Consumer called in and reported that she has had two outbreaks of shingles, since getting ZOSTAVAX (reported as about 9 month after getting the shot). Patient currently had the rash all over both of her legs and arms, on face and possibly in her ear. At the time of the report, the patient had not recovered from the shingles. The patient did not receive treatment for the shingles. No labs diagnostics studies were performed. It was reported that patient sought medical attention by contact the physician's office. Additional information has been requested.
Sickness; Patient received more than half a dose initially; some leakage once needle was drawn out of patient; This spontaneous case was reported by a pharmacist and describes the occurrence of ILLNESS (Sickness), UNDERDOSE (Patient received more than half a dose initially) and DEVICE CONNECTION ISSUE (some leakage once needle was drawn out of patient) in a 20-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036c21a) for COVID-19 vaccination.     No Medical History information was reported.    On 15-May-2021 at 2:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-May-2021, the patient experienced ILLNESS (Sickness) and DEVICE CONNECTION ISSUE (some leakage once needle was drawn out of patient). 15-May-2021, the patient experienced UNDERDOSE (Patient received more than half a dose initially). At the time of the report, ILLNESS (Sickness) and DEVICE CONNECTION ISSUE (some leakage once needle was drawn out of patient) outcome was unknown and UNDERDOSE (Patient received more than half a dose initially) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment information was provided by the reporter.   This case was linked to MOD-2021-272290 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 09-Jul-2021: Updated the start date of first dose of vaccine and event. On 29-Jul-2021: significant follow up appended: New events captured, Suspect products information was captured, Patient demographic details captured.
Cellulitis (erythema, induration, tenderness, lymphadenopathy, and fever) in arm around injection site.  Appeared 18 hours after vaccination.  Responded to clindamycin.
p/vax pt jerked against the needle & nurse struggled;mom felt something went wrong as a lot of fluid dripped own to elbow on arm;pt exp two inj holes on arm & a welt an inch from two hole sites;
Mild rash to right antecubital, and itching. Benadryl 25 mg PO given.
Received HPV vaccine 3 days before the 2nd shot of the moderna; muscle pain; joint pain; headache; shoulder pain; cold; had a little lump; With the 1st dose got arm pain; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (With the 1st dose got arm pain), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received HPV vaccine 3 days before the 2nd shot of the moderna), NASOPHARYNGITIS (cold), INJECTION SITE MASS (had a little lump) and HEADACHE (headache) in an 18-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 022M20A and 042L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Previously administered products included for an unreported indication: HPV VACCINE (Received HPV vaccine 3 days before the 2nd shot of the moderna).   On 14-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 14-Mar-2021, the patient experienced NASOPHARYNGITIS (cold) and INJECTION SITE MASS (had a little lump). On 15-Mar-2021, the patient experienced HEADACHE (headache) and ARTHRALGIA (shoulder pain). On 16-Mar-2021, the patient experienced MYALGIA (muscle pain) and ARTHRALGIA (joint pain). On an unknown date, the patient experienced PAIN (With the 1st dose got arm pain) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received HPV vaccine 3 days before the 2nd shot of the moderna). The patient was treated with IBUPROFEN (ADVIL 12 HOUR) at an unspecified dose and frequency and PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, PAIN (With the 1st dose got arm pain), NASOPHARYNGITIS (cold), INJECTION SITE MASS (had a little lump), HEADACHE (headache) and ARTHRALGIA (shoulder pain) had resolved and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Received HPV vaccine 3 days before the 2nd shot of the moderna), MYALGIA (muscle pain) and ARTHRALGIA (joint pain) outcome was unknown.            Action taken with mRNA-1273 in response to the event was not applicable.
Red, blotchy area that's warm to the touch; Red, blotchy area that's warm to the touch; This spontaneous case was reported by a consumer and describes the occurrence of RASH ERYTHEMATOUS (Red, blotchy area that's warm to the touch) and VACCINATION SITE WARMTH (Red, blotchy area that's warm to the touch) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH ERYTHEMATOUS (Red, blotchy area that's warm to the touch) and VACCINATION SITE WARMTH (Red, blotchy area that's warm to the touch). At the time of the report, RASH ERYTHEMATOUS (Red, blotchy area that's warm to the touch) and VACCINATION SITE WARMTH (Red, blotchy area that's warm to the touch) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Patient under 18 years got a dose of the Moderna vaccine; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Patient under 18 years got a dose of the Moderna vaccine) in a 13-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 939906) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 28-Sep-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Patient under 18 years got a dose of the Moderna vaccine). On 28-Sep-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Patient under 18 years got a dose of the Moderna vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant drug was not reported. Treatment medication was not reported.   This case was linked to MOD-2021-336661 (Patient Link).
Patient received the wrong dose  on 02/16/2022 of 0.2ml Lot#FK5127 Pfizer Previous dose on 10/15/2021 was correct 0.3ml Lot #ff2593 Pfizer
I had my 2nd dose of the Shangrix at 4:00 in the afternoon, by 8:00 that same night I obtained a severe headache. Next morning, I woke up extremely tired, still had the headache as time went on, I had chills, fever, body aches everywhere, no appetite and still very tired, neck hurts and have some dizziness. This was 18 hours later and still continue.
low grade fever 99.6°F; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (low grade fever 99.6°F) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025A21A) for COVID-19 vaccination.     The patient's past medical history included Fever. Concomitant products included SIMVASTATIN for an unknown indication.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PYREXIA (low grade fever 99.6°F). The patient was treated with IBUPROFEN at an unspecified dose and frequency. At the time of the report, PYREXIA (low grade fever 99.6°F) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Previous tendon pain at joint sites (from Lyme disease) returned full force (had been gone since 2012); Previous headache became constant (last headache was 1998);  Memory issues and word-finding problems (previous Lyme symptoms which had been gone since 1995); Constant nausea (only alleviated partially by acupressure band on wrists) These symptoms are still ongoing...it's day 17 post 2nd vaccination.
Moderna COVID-19 Vaccine EUA   Beginning shortly after the vaccination I felt discomfort in my right armpit and breast.  It became quite painful and feels heavy and uncomfortable.  It will sometimes feel a bit better but then return.  This has now been 2 weeks.
Administration of Expired Vaccine; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administration of Expired Vaccine) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 08-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administration of Expired Vaccine). On 08-Jun-2021, EXPIRED PRODUCT ADMINISTERED (Administration of Expired Vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   No Concomitant medication were provided. No Treatment medication were provided.   This case was linked to MOD-2021-237427 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 16-AUG-2021: TCR received: NNI: Follow-up information included no new information
Approx 2 days after immunization pt experienced (R) arm pain, numbness, decreased movt/strength. Seen for this 1/7 - worsened symptoms so then admitted x 2-3 days to medical center. Followed by neurology there, EMG and other testing done, given splint, receiving occupat therapy needs f/u with neurology.
This spontaneous report was received from a Registered Nurse, concerning 7 patients of unknown age and gender. No information was provided regarding the patient's medical history, concurrent conditions or concomitant medications. On an unknown date, the patients were vaccinated with improperly stored GARDASIL 9 for prophylaxis, lot # N021571 and expiration date on 29-APR-2020 (dose, route of administration and anatomical location were not reported). The administered doses of the vaccine experienced an unspecified temperature excursion of below 32 F for an unspecified timeframe, as recorded by a data logger. The vaccines had had multiple unspecified previous temperature excursions below 32 F for an unspecified time frame. There was no adverse effects reported. No product quality complaint was involved.
Expired vaccine used; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a 70-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 13-Aug-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitants were provided. No treatment was provided. The vaccine was administered after 11 days from  time from first puncture.   This case was linked to MOD-2021-333942 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 28-Sep-2021: Follow-up contains no new information, but initial version missed to capture therapy onset and event onset date, batch number corrected and added.
The afternoon of the day after receiving Flumist, mother and speech therapist noticed that patient's left side of his face was drawn up (in actuality, the right side was drooping).
my husband now has Covid; my husband now has Covid; This is a spontaneous report from a contactable consumer. This consumer reported for a male patient (husband). A male patient of an unspecified age was received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot Number: unknown) as a dose 2, via an unspecified route of administration in Jan2021 as dose 2, single, and first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot Number: unknown), via an unspecified route of administration in Jan2021 as dose 1, single for covid-19 immunisation. Medical history and concomitant medications were not reported. On an unspecified date on 2021,  my husband now has Covid. The reporter reported that, after receiving two doses of the Pfizer vaccine in Jan my husband now has Covid. I probably do also. I just did not get tested. The lab data included tested Covid on an unspecified date on 2021.  Information about lot/batch number has been requested.
Site: Itching at Injection Site-Medium, Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Systemic: Allergic: Rash (specify: facial area, extremeties)-Mild, Additional Details: Patient advised to take antihistamine for itch and to f/u with PCP if worsened symptoms
Patient is only 17 years old and not the right age requirement to receive Moderna Vaccine. Moderna Vaccine was administered.
Pfizer 3/23 and 4/13. Positive on 12/14
Expired dose of kinrix was administered; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 4-year-old male patient who received DTPa-IPV (Kinrix) (batch number D24G7, expiry date 4th June 2022) for prophylaxis.   Co-suspect products included dtpa-ipv vaccine pre-filled syringe device (Kinrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 8th June 2022, the patient received Kinrix and Kinrix Pre-Filled Syringe Device. On 8th June 2022, unknown after receiving Kinrix and Kinrix Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date:08-JUN-2022 Reporter's Comments:  The health care professional reported an expired dose of Kinrix was administered to a patient. The reporter consented to follow up. The vaccine administration facility was the same as primary reporter. Additional Supportive Information: The patient was administered an expired dose of Kinrix, which led to expired vaccine used.
Pt ran a fever 106.2 ax. Despite 9  4 hour apprx doses Tylenol.